Browsing Tag
Dr. Reddy’s Laboratories
66 posts
Glenmark Pharmaceuticals (NSE: GLENMARK) launches GLIPIQ semaglutide in India at Rs 325 a week as generic GLP-1 era starts
Glenmark Pharmaceuticals launches GLIPIQ semaglutide in India from Rs 325 a week. Analysis of pricing, competition, and what it means for GLP-1 access. Read more.
NATCO Pharma (NSE: NATCOPHARM) launches cheapest semaglutide in India at Rs 1,290 on Day 1 of patent expiry
NATCO Pharma launches generic semaglutide in India at INR 1,290 on Day 1 of patent expiry. What it means for GLP-1 markets. Read the full analysis.
Coya Therapeutics gets FDA green light for Phase 2 ALS trial with COYA 302
Coya Therapeutics receives FDA clearance to initiate a Phase 2 trial of COYA 302 for ALS. Find out what this means for investors and the ALS drug pipeline.
Pharma stock watch: Are Indian midcaps like Glenmark better positioned than the giants?
Are Indian midcap pharma stocks like Glenmark set to outperform giants like Sun and Cipla? Explore 2025 trends, biotech bets, and market sentiment shifts.
Bloodbath on Dalal Street! 20 Indian stocks crash amid Trump tariffs, RBI rate cut and pharma panic
Discover why 20 major Indian stocks plunged on April 9, as global tariff tensions and RBI's rate cut roil investor confidence across key sectors.
Dr. Reddy’s Laboratories recalls Levetiracetam Injection in U.S. over mislabeling concerns
Dr. Reddy’s Laboratories Limited has initiated a nationwide recall of a batch of Levetiracetam in 0.75% Sodium Chloride…
Dr Reddy’s launches toripalimab in India as first immuno-oncology drug for nasopharyngeal carcinoma
Dr. Reddy’s Laboratories Ltd. announced a significant milestone in its oncology portfolio with the launch of Toripalimab in…
Dr. Reddy’s joins forces with Gilead Sciences to launch HIV drug Lenacapavir in India and 120 countries
In a historic development for HIV treatment worldwide, Dr. Reddy’s Laboratories has announced a new partnership with Gilead…
Dr. Reddy’s Laboratories takes $620m gamble in Switzerland: Could this bold move dominate Europe?
Dr. Reddy’s Laboratories, the Indian pharmaceutical giant, has solidified its European ambitions with a monumental $620 million investment…
Dr. Reddy’s Laboratories secures key European endorsement for Rituximab biosimilar
In a significant development for the pharmaceutical industry, Dr. Reddy’s Laboratories Ltd. has received a positive opinion from…